FDA approves Aimmune drug as 1st treatment for peanut allergy
from BioPharma Dive
The Food and Drug Administration approved the first treatment for peanut allergy, clearing Aimmune Therapeutics' immunotherapy Palforzia for use by the more than one million children and teens aged 4 to 17 in the U.S. who can't tolerate the food. Approval gives Aimmune a head start of about six months on its nearest rival, DBV Technologies, which is using a patch-based delivery system to expose patients to increasing amounts of peanut antigen.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063